Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07147218 · ClinicalTrials.gov registry record · NA

Accelerated TMS for MDD

A NA study of Major Depressive Disorder, sponsored by Neuronetics.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
3
Study locations

NCT07147218 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Neuronetics. The registered enrollment target is 50 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07147218, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neuronetics.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).

Conditions Studied

Interventions

  • DEVICE TMS

Study Locations (3)

New York

  • Brighter Neurotherapeutics - New York

North Carolina

  • TMS of the Carolinas - Charlotte

Washington

  • New chapter TMS - Spokane

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-21
Est. Completion 2027-12-31
Phase NA

Sponsor

Neuronetics

11 total trials

What the Registry Record Tells You About NCT07147218

The ClinicalTrials.gov registry entry for NCT07147218 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The listed sponsor is Neuronetics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which TMS is the first listed.

NCT07147218 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, North Carolina, Washington.

Frequently Asked Questions

What is clinical trial NCT07147218 about?

NCT07147218 is a clinical study titled "Accelerated TMS for MDD". An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).

What is the current status of trial NCT07147218?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-08-21. Estimated completion is 2027-12-31.

What conditions does trial NCT07147218 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT07147218?

The interventions under investigation include: TMS (DEVICE).

Who is sponsoring clinical trial NCT07147218?

This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07147218 being conducted?

This trial has 3 study locations across New York, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.